A comparison chart lists one receptor beside semaglutide, two beside tirzepatide and three beside retatrutide. It looks like a ready-made ranking. Yet those counts describe which biological targets a molecule activates, not how much weight a person will lose or how safely they will lose it.[1][2][3] The useful question is what each target contributes, how the molecule behaves at it, and which experiments support the proposed benefit. Counting targets alone skips all three questions.
Start with the signals, not the score
A receptor is a protein that receives a molecular signal. An agonist binds to a receptor and activates it. GLP-1, short for glucagon-like peptide-1, and GIP, glucose-dependent insulinotropic polypeptide, are incretin hormones involved in insulin responses to food.[1] Their receptors also participate in biology beyond insulin secretion.
The semaglutide label describes GLP-1 as a regulator of appetite and calorie intake, with receptors in brain regions involved in appetite regulation. Semaglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner: these effects depend on the surrounding glucose conditions.[3]
GIP has its own receptor and activity profile. The tirzepatide label identifies both GIP and GLP-1 receptors in appetite-related brain regions, while specifically describing additional contributions from GIP to food-intake regulation as suggested by nonclinical studies.[4] That wording matters: a biological possibility and a fully established human mechanism are different claims.
Glucagon adds another target. In the triple-agonist discovery abstract, glucagon-receptor activity contributed to increased energy expenditure in obese mice.[2] This supplies a research rationale for combining targets, while leaving human effects to be established separately.
A receptor map is a map of possibilities
A molecule can activate several receptors without activating them equally. These examples show what the familiar single, dual and triple descriptions actually identify.
| Molecule | Receptor map | What the cited evidence establishes | What the count cannot establish |
|---|---|---|---|
| Semaglutide | GLP-1 | The official label describes selective GLP-1 receptor activation.[3] | A clinical ranking against every multi-target molecule. |
| Tirzepatide | GIP + GLP-1 | The label identifies both targets; discovery cell assays found different relative activities at them.[1][4] | Equal activity at both receptors or an isolated GIP contribution in people. |
| Retatrutide, LY3437943 | Glucagon + GIP + GLP-1 | The discovery abstract reports balanced glucagon/GLP-1 activity and greater GIP activity in vitro.[2] | Three times the effect, or proof of superior human outcomes. |
“In vitro” means outside a living organism, such as in a cell assay. A profile measured there is a valuable description of receptor pharmacology. It is not a complete description of what happens when the molecule reaches different tissues in a person.
The important difference between binding and response
Tirzepatide's discovery paper, using its identifier LY3298176, illustrates why a single count loses information. In receptor-binding experiments, affinity at the GIP receptor was comparable to native GIP, while affinity at the GLP-1 receptor was approximately fivefold weaker than native GLP-1.[1] Affinity describes how readily a molecule binds under the assay conditions.
A signaling assay asks a different question: how much molecule is needed to produce a measured cellular response? In those experiments, tirzepatide's potency was similar to native GIP at the GIP receptor and approximately thirteenfold weaker than native GLP-1 at the GLP-1 receptor.[1] The two comparisons use different native hormones as reference points; they are not interchangeable measures of clinical strength.
The researchers conducted the relevant cell-line binding and signaling assays without albumin, a blood protein, to avoid its binding effects complicating comparisons with native hormones.[1] This is a concrete reminder that measurements depend on experimental conditions. Neither the receptor count nor one laboratory potency ratio can predict a person's response to a finished medicine.
Follow the evidence from cells to animals to people
The mouse experiments contain a useful negative result. A long-acting GIP agonist lowered fasting blood glucose but did not change body weight or body composition in the tested obese-mouse model.[1] Activity at a relevant receptor did not automatically produce every desired outcome.
In that model, the dual agonist produced greater weight loss than semaglutide, with a larger and more prolonged reduction in food intake and a small increase in energy expenditure.[1] Those findings support hypotheses about combined activity in mice. They do not quantify GIP's independent contribution in humans.
The triple-agonist abstract similarly attributes additional weight loss in obese mice to glucagon-mediated energy expenditure alongside reduced calorie intake.[2] Its human component was an early phase 1 study reporting a tolerability signal and weight reduction. That historical experiment did not demonstrate the same energy-expenditure mechanism in people, and a 2022 abstract cannot describe the current development landscape.[2]
The 2018 tirzepatide paper reported glucose and weight improvements in early human studies, but acknowledged their small size and short duration. It also stated that the clinical design could not distinguish GIP's contribution from GLP-1's.[1] Clinical comparisons need their own populations, formulations, routes, comparators and endpoints. For molecule-specific clinical discussions, see the existing articles on retatrutide and survodutide.
More targets do not settle the safety question
Neither a receptor map nor an encouraging animal result establishes safety. Wegovy and Zepbound labels warn about severe gastrointestinal reactions, pancreatitis, gallbladder disease and kidney injury associated with fluid depletion.[3][4] These warnings belong to those products; they are not a measured safety ranking for every molecule sharing a target.
Both labels carry boxed warnings about thyroid C-cell tumors in rodents, while stating that human relevance is unknown. They also contraindicate use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.[3][4] A rodent warning is consequential without being proof that these drugs cause human cancer.
Laboratory research materials should not be consumed or self-administered. Even a well-characterized reagent does not thereby become a finished medicine with established formulation, clinical benefit and human safety. Reconstitution cannot establish those properties. FDA warns that unapproved versions lack its premarket safety, effectiveness and quality review, and identifies companies selling products for human use under false research labels.[5] That warning concerns a documented marketing practice, not a finding that every laboratory reagent is dirty or untested. Receptor biology can explain an experimental rationale; it cannot authorize personal use.
Source note: This article uses the full 2018 dual-agonist discovery paper, the original abstract of the 2022 triple-agonist discovery paper, relevant current label sections and FDA safety information retrieved October 23, 2026. Historical experiments, cell assays, mouse findings and human observations are distinguished. This is editorial source review, not medical review or a Chudik experiment.
Sources and further reading
- Coskun et al.: Dual GIP/GLP-1 agonist discovery (2018; full paper)
- Coskun et al.: Triple glucagon/GIP/GLP-1 agonist discovery (2022; original abstract)
- Wegovy: current semaglutide prescribing information
- Zepbound: current tirzepatide prescribing information
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss